Hydromer Reports 11% Revenue Growth and Return to Profitability in Q3 2025

Hydromer, Inc. reported preliminary unaudited financial results for the quarter ended September 30, 2025, showing significant improvement in both revenue and profitability. The medical device coating technology company generated $0.91 million in revenue during the third quarter, representing an 11% increase compared to $0.81 million in the same period last year.

The company returned to profitability with net income of $53,000 for the quarter, marking an important milestone after previous periods of financial challenges. These preliminary results are based on current management information and remain subject to completion of the company's 2025 year-end financial reporting processes, reviews, audit, and potential adjustments.

Michael Torti, CEO of Hydromer, stated that the company is "pleased to report continued top line growth and return to a profit-making quarter." He attributed the positive performance to strong customer loyalty and growth from new customers entering the company's production coating line-up. The company continues to invest in infrastructure and equipment while maintaining focus on new product development.

Importantly, Torti addressed concerns about the company's stock valuation and trading difficulties, stating that management "will be taking steps to return HYDI to the OTCID Basic Market." This move could potentially improve stock liquidity and valuation for investors who have faced challenges with the artificially low stock price.

For investors and industry observers, these results demonstrate Hydromer's ability to maintain growth momentum in the competitive medical device coating market. The company's focus on operational efficiency, customer partnerships, and next-generation technology development appears to be yielding positive financial results. The planned return to the OTCID Basic Market could provide additional stability and visibility for the company's stock, which has been trading on the OTC markets under the symbol HYDI.

The medical device coating industry represents a critical segment of the healthcare technology sector, with coatings playing essential roles in improving device performance, safety, and patient outcomes. Hydromer's position as a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for over 44 years provides context for understanding the significance of these financial improvements. The company's ability to return to profitability while maintaining revenue growth suggests effective management of operational costs and strategic investments.

View the original release on www.newmediawire.com for complete details about the preliminary financial results and forward-looking statements. These developments are particularly relevant for stakeholders in the medical device manufacturing sector, as they indicate continued innovation and financial stability in specialized coating technologies that enhance medical device performance and patient safety.